Tesamorlin
Secretagogue Peptide

Tesamorlin

EGRIFTATH9507

A 44-amino acid GHRH analog that stimulates pituitary GH secretion, studied for visceral adipose tissue reduction in clinical research. Premium Research Peptide.

Dosage
Third-Party TestingIdentity, purity, and batch consistency reviewed by an independent lab.
$69.99
Bundle & Save
1
Estimated delivery Mon, May 11Sun, May 17
Free shipping on orders over $99
Free shipment protection · Lost, damaged, stolen — we replace it.
Overnight shipping available
Research use only. Not for human consumption. Sold exclusively for qualified research.

Similar research products

Based on the current compound category and related research focus.

Third-Party Testing

We use third-party testing to give you a clearer look at identity, purity, and batch consistency before a product reaches your lab. Our testing is done by Freedom Diagnostics.

We use HPLC and/or Mass Spectrometry to make sure the peptide is what it says it is, with a clear look at purity and any major impurities we would want you to know about.

This helps us understand how much actual peptide is in the vial, separate from things like water, salts, or counterions, so the batch information is more useful and honest.

We check for bacterial endotoxins because cleaner documentation matters, especially for researchers working with sensitive cell culture or in vivo settings.

Additional vials from the same lot can be compared against the primary sample, giving another layer of confidence that the batch is consistent from vial to vial.

Certificate of Analysis Documents

  • Latest
    99.32%
    Purity
    View
    Variant
    Tesamorlin 10mg
    Lot #
    B0907
    Labeled
    10mg
    Actual
    10.11mg
    Tested
    Jan 18, 2026

Clinical & preclinical references

Peer-reviewed studies referenced for educational purposes only. Not intended as medical advice or product claims.

Journal of Clinical Endocrinology & Metabolism

Effects of tesamorlin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials

Falutz J, et al.

2010 / PMID 20554713
View Source
Lancet HIV

Effects of tesamorlin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial

Stanley TL, et al.

2019 / PMID 31611038
View Source
Archives of Neurology

Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults

Baker LD, et al.

2012 / PMID 22869065
View Source
Journal of Clinical Endocrinology & Metabolism

The Growth Hormone Releasing Hormone Analogue, Tesamorlin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV

Adrian S, et al.

2019 / PMID 31050749
View Source
FDA

EGRIFTA (tesamorlin) Prescribing Information

Theratechnologies Inc.

2025
View Source
Journal of Clinical Endocrinology & Metabolism

Effects of tesamorlin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials

Falutz J, et al.

2010 / PMID 20554713
View Source
Lancet HIV

Effects of tesamorlin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial

Stanley TL, et al.

2019 / PMID 31611038
View Source
Archives of Neurology

Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults

Baker LD, et al.

2012 / PMID 22869065
View Source
Journal of Clinical Endocrinology & Metabolism

The Growth Hormone Releasing Hormone Analogue, Tesamorlin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV

Adrian S, et al.

2019 / PMID 31050749
View Source
FDA

EGRIFTA (tesamorlin) Prescribing Information

Theratechnologies Inc.

2025
View Source
Journal of Clinical Endocrinology & Metabolism

Effects of tesamorlin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials

Falutz J, et al.

2010 / PMID 20554713
View Source
Lancet HIV

Effects of tesamorlin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial

Stanley TL, et al.

2019 / PMID 31611038
View Source
Archives of Neurology

Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults

Baker LD, et al.

2012 / PMID 22869065
View Source
Journal of Clinical Endocrinology & Metabolism

The Growth Hormone Releasing Hormone Analogue, Tesamorlin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV

Adrian S, et al.

2019 / PMID 31050749
View Source
FDA

EGRIFTA (tesamorlin) Prescribing Information

Theratechnologies Inc.

2025
View Source
Journal of Clinical Endocrinology & Metabolism

Effects of tesamorlin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials

Falutz J, et al.

2010 / PMID 20554713
View Source
Lancet HIV

Effects of tesamorlin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial

Stanley TL, et al.

2019 / PMID 31611038
View Source
Archives of Neurology

Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults

Baker LD, et al.

2012 / PMID 22869065
View Source
Journal of Clinical Endocrinology & Metabolism

The Growth Hormone Releasing Hormone Analogue, Tesamorlin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV

Adrian S, et al.

2019 / PMID 31050749
View Source
FDA

EGRIFTA (tesamorlin) Prescribing Information

Theratechnologies Inc.

2025
View Source
Journal of Clinical Endocrinology & Metabolism

Effects of tesamorlin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials

Falutz J, et al.

2010 / PMID 20554713
View Source
Lancet HIV

Effects of tesamorlin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial

Stanley TL, et al.

2019 / PMID 31611038
View Source
Archives of Neurology

Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults

Baker LD, et al.

2012 / PMID 22869065
View Source
Journal of Clinical Endocrinology & Metabolism

The Growth Hormone Releasing Hormone Analogue, Tesamorlin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV

Adrian S, et al.

2019 / PMID 31050749
View Source
FDA

EGRIFTA (tesamorlin) Prescribing Information

Theratechnologies Inc.

2025
View Source
Journal of Clinical Endocrinology & Metabolism

Effects of tesamorlin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials

Falutz J, et al.

2010 / PMID 20554713
View Source
Lancet HIV

Effects of tesamorlin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial

Stanley TL, et al.

2019 / PMID 31611038
View Source
Archives of Neurology

Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults

Baker LD, et al.

2012 / PMID 22869065
View Source
Journal of Clinical Endocrinology & Metabolism

The Growth Hormone Releasing Hormone Analogue, Tesamorlin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV

Adrian S, et al.

2019 / PMID 31050749
View Source
FDA

EGRIFTA (tesamorlin) Prescribing Information

Theratechnologies Inc.

2025
View Source
Research Use Only

Important Research Notice

Not for human consumption. This product is sold exclusively for research and educational purposes. It is not intended to diagnose, treat, cure, or prevent any disease.

Clinical trial data and research findings on this page are sourced from peer-reviewed journals and official publications. They are provided for educational reference only and should not be interpreted as medical advice or product claims.

By purchasing this product, you confirm that you are a qualified researcher and will use it in accordance with all applicable laws and regulations.